South Korea
· Delayed Price · Currency is KRW GeneOne Life Science Statistics
Total Valuation
GeneOne Life Science has a market cap or net worth of KRW 169.64 billion. The enterprise value is 183.87 billion.
| Market Cap | 169.64B |
| Enterprise Value | 183.87B |
Important Dates
The last earnings date was Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneOne Life Science has 79.83 million shares outstanding. The number of shares has increased by 1.26% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 79.83M |
| Shares Change (YoY) | +1.26% |
| Shares Change (QoQ) | +1.93% |
| Owned by Insiders (%) | 11.61% |
| Owned by Institutions (%) | 4.77% |
| Float | 70.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.09 |
| PB Ratio | 1.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.50 |
| EV / Sales | 4.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.90 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.25 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.91 |
| Interest Coverage | -44.06 |
Financial Efficiency
Return on equity (ROE) is -54.64% and return on invested capital (ROIC) is -19.38%.
| Return on Equity (ROE) | -54.64% |
| Return on Assets (ROA) | -16.43% |
| Return on Capital (ROIC) | -19.38% |
| Revenue Per Employee | 558.94M |
| Profits Per Employee | -1.01B |
| Employee Count | 73 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 2.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.89% in the last 52 weeks. The beta is -2.10, so GeneOne Life Science's price volatility has been lower than the market average.
| Beta (5Y) | -2.10 |
| 52-Week Price Change | -28.89% |
| 50-Day Moving Average | 2,415.50 |
| 200-Day Moving Average | 2,509.95 |
| Relative Strength Index (RSI) | 37.24 |
| Average Volume (20 Days) | 641,366 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GeneOne Life Science had revenue of KRW 40.80 billion and -73.64 billion in losses. Loss per share was -937.97.
| Revenue | 40.80B |
| Gross Profit | -6.59B |
| Operating Income | -45.90B |
| Pretax Income | -73.46B |
| Net Income | -73.64B |
| EBITDA | -28.28B |
| EBIT | -45.90B |
| Loss Per Share | -937.97 |
Balance Sheet
The company has 4.50 billion in cash and 18.73 billion in debt, giving a net cash position of -14.23 billion or -178.24 per share.
| Cash & Cash Equivalents | 4.50B |
| Total Debt | 18.73B |
| Net Cash | -14.23B |
| Net Cash Per Share | -178.24 |
| Equity (Book Value) | 105.44B |
| Book Value Per Share | 1,320.77 |
| Working Capital | 6.08B |
Cash Flow
In the last 12 months, operating cash flow was -16.87 billion and capital expenditures -3.80 billion, giving a free cash flow of -20.67 billion.
| Operating Cash Flow | -16.87B |
| Capital Expenditures | -3.80B |
| Free Cash Flow | -20.67B |
| FCF Per Share | -258.93 |
Margins
Gross margin is -16.15%, with operating and profit margins of -112.48% and -180.49%.
| Gross Margin | -16.15% |
| Operating Margin | -112.48% |
| Pretax Margin | -180.05% |
| Profit Margin | -180.49% |
| EBITDA Margin | -69.32% |
| EBIT Margin | -112.48% |
| FCF Margin | -50.66% |
Dividends & Yields
GeneOne Life Science does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.26% |
| Shareholder Yield | -1.26% |
| Earnings Yield | -44.14% |
| FCF Yield | -12.18% |
Stock Splits
The last stock split was on December 3, 2021. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 3, 2021 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
GeneOne Life Science has an Altman Z-Score of 0.2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.2 |
| Piotroski F-Score | n/a |